<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541735</url>
  </required_header>
  <id_info>
    <org_study_id>IBP1301-93</org_study_id>
    <nct_id>NCT01541735</nct_id>
  </id_info>
  <brief_title>Pantoprazole on Insulin Secretion in Diabetes</brief_title>
  <acronym>IBP</acronym>
  <official_title>Effect of Pantoprazole on Insulin Secretion in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of pantoprazole on insulin secretion in
      drug-naïve patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus (T2DM) has become a major health problem worldwide with a high
      prevalence and related mortality, and a high rate of disability in the economically active.
      In Mexico the prevalence was 14.4% reported one of the highest in Latin America and estimated
      a cost of $ 778 million allocated for this disease in 2010, i.e., the tenth place worldwide.
      Within its pathophysiology are alterations in the secretion and insulin action, qualitatively
      and quantitatively, which implies a challenge for long-term metabolic control with the
      pharmacological arsenal available today. Since the function of pancreatic β cell decreases as
      a function of time and lack of control is essential metabolic find drugs that can preserve
      pancreatic cell mass and even promote neogenesis, with the aim of restoring the physiological
      secretion of insulin have been lost in the early stages of type 2 diabetes to achieve optimal
      glycemic control sustained over time to avoid complications and reduce the costs associated
      with the disease.

      Have been evaluated in animal models with promising results Proton Pumps Inhibitors (PPI) for
      the restoration of glucose and the preservation of pancreatic cell function, including
      promoting its growth through increased levels of gastrin, which appears to act as a growth
      factor. However, at present no such mechanisms have been evaluated in humans, it would be
      interesting to assess the effect of administration of a PPI such as pantoprazole is, on the
      phases of insulin secretion in patients with T2DM recent diagnosis.

      Material and Methods: Randomized, double-blind, placebo controlled clinical trial.
      Population: 14 drug-naive adults patients with T2DM and obesity.
      Hyperglycemic-hyperinsulinemic clamp to assess the phases of insulin secretion. Intervention
      for 45 days: pantoprazole 40mg or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First Phase of Insulin Secretion</measure>
    <time_frame>Change from Baseline at 45 days. (plus or minus 3 days)</time_frame>
    <description>The hyperglycemic-hyperinsulinemic clamp technique is perform to assess the phases of insulin secretion: first, late and total insulin secretion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Second Phase of Insulin Secretion</measure>
    <time_frame>Baseline and 45 day</time_frame>
    <description>Change from baseline in first phase insulin secretion at 45 day. (plus or minus 3 days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Insulin Secretion</measure>
    <time_frame>Change from baseline of total insulin secretion at 45 day (plus or minus 3 days)</time_frame>
    <description>The hyperglycemic-hyperinsulinemic clamp technique is performed to assess the total insulin secretion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycated Hemoglobin A1C</measure>
    <time_frame>Change from Baseline in glycated hemoglobin A1C at 45 day.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of calcined magnesia, capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The pantoprazole will be administered in 40mg capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.</description>
    <arm_group_label>Pantoprazole</arm_group_label>
    <other_name>Pantozol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo 40 mg dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Drug-Naive

          -  No complications

          -  HbA1c 7 to &lt; 9%

          -  Fasting plasma glucose &lt; 210mg/dl

          -  Body mass index 30.0 to 39.9 and body weight stable for at least 3 months before the
             study

          -  Non smokers

          -  Blood pressure &lt; 130/80

        Exclusion Criteria:

          -  Diabetes complications

          -  Women pregnant or stage of lactation

          -  Hepatic, renal, autoimmune disease

          -  Take drugs with effects on insulin secretion

          -  Zollinger-Ellison disease

          -  Gastric or pancreatic tumor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Gonzalez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social. Centro Medico Nacional de Occidente. Unidad de Investigación Médica en Epidemiologia Clínica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Mexicano del Seguro Social. Hospital de Especialidades.</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44380</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <results_first_submitted>July 27, 2013</results_first_submitted>
  <results_first_submitted_qc>January 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2014</results_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Manuel Gonzalez Ortiz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Pantoprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pantoprazole</title>
          <description>The pantoprazole will be administered in 40mg capsules PO, 30 minutes before to breakfast during 45 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo of calcined magnesia, capsules PO, 30 minutes before to breakfast during 45 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pantoprazole</title>
          <description>The pantoprazole will be administered in 40mg capsules</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo of calcined magnesia, capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.8" spread="7.1"/>
                    <measurement group_id="B2" value="46.2" spread="9.6"/>
                    <measurement group_id="B3" value="48.0" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>First Phase of Insulin Secretion</title>
        <description>The hyperglycemic-hyperinsulinemic clamp technique is perform to assess the phases of insulin secretion: first, late and total insulin secretion.</description>
        <time_frame>Change from Baseline at 45 days. (plus or minus 3 days)</time_frame>
        <population>The analysis was determined per protocol and sample size was calculated whit the formula for clinical trial</population>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole</title>
            <description>The pantoprazole will be administered in 40mg capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo of calcined magnesia, capsules</description>
          </group>
        </group_list>
        <measure>
          <title>First Phase of Insulin Secretion</title>
          <description>The hyperglycemic-hyperinsulinemic clamp technique is perform to assess the phases of insulin secretion: first, late and total insulin secretion.</description>
          <population>The analysis was determined per protocol and sample size was calculated whit the formula for clinical trial</population>
          <units>µU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="5.5"/>
                    <measurement group_id="O2" value="15.9" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycated Hemoglobin A1C</title>
        <time_frame>Change from Baseline in glycated hemoglobin A1C at 45 day.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole</title>
            <description>The pantoprazole will be administered in 40mg capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo of calcined magnesia, capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Glycated Hemoglobin A1C</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread=".38"/>
                    <measurement group_id="O2" value="7.8" spread=".45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Second Phase of Insulin Secretion</title>
        <description>Change from baseline in first phase insulin secretion at 45 day. (plus or minus 3 days)</description>
        <time_frame>Baseline and 45 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole</title>
            <description>The pantoprazole will be administered in 40mg capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo of calcined magnesia, capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Second Phase of Insulin Secretion</title>
          <description>Change from baseline in first phase insulin secretion at 45 day. (plus or minus 3 days)</description>
          <units>µU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="21.2"/>
                    <measurement group_id="O2" value="38.4" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Insulin Secretion</title>
        <description>The hyperglycemic-hyperinsulinemic clamp technique is performed to assess the total insulin secretion</description>
        <time_frame>Change from baseline of total insulin secretion at 45 day (plus or minus 3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole</title>
            <description>The pantoprazole will be administered in 40mg capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo of calcined magnesia, capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Total Insulin Secretion</title>
          <description>The hyperglycemic-hyperinsulinemic clamp technique is performed to assess the total insulin secretion</description>
          <units>µU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="15.8"/>
                    <measurement group_id="O2" value="31.5" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pantoprazole</title>
          <description>The pantoprazole will be administered in 40mg capsules</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo of calcined magnesia, capsules</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The intervention time was short to evaluate a total change in the primary outcome variables</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>PhD. Manuel González Ortiz</name_or_title>
      <organization>Instituto Mexicano del Seguro Social</organization>
      <phone>33 36176000 ext 31494</phone>
      <email>uiec@prodigy.net.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

